Rivera-Caravaca JM, et al. - The clinicians examined the incidence and risk of major bleeding, ischaemic stroke, and mortality of atrial fibrillation (AF) in patients taking acenocoumarol plus antiplatelet therapy vs individuals taking only acenocoumarol monotherapy. When antiplatelet therapy was combined with acenocoumarol, the risk of bleeding was found to be higher in AF patients. However, the risk of mortality and stroke was not significantly different between both the study cohorts.